Clinical Trial Update: Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating the combination of cabozantinib and nivolumab for refractory metastatic microsatellite-stable colorectal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Colorectal Adenocarcinoma, Colon Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING